z-logo
open-access-imgOpen Access
Modifying effect of XmnI, BCL11A, and HBS1L-MYB on clinical appearances: A study on β-thalassemia and hemoglobin E/β-thalassemia patients in Indonesia
Author(s) -
Lantip Rujito,
Muhammad Ridwan Basalamah,
Wahyu Siswandari,
Joko Setyono,
Gondo Wulandari,
Sri Mulatsih,
Abdul Salam M. Sofro,
Ahmad Hamim Sadewa,
Sutaryo Sutaryo
Publication year - 2016
Publication title -
hematology/oncology and stem cell therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.666
H-Index - 22
eISSN - 1658-3876
pISSN - 2589-0646
DOI - 10.1016/j.hemonc.2016.02.003
Subject(s) - fetal hemoglobin , locus (genetics) , genotyping , thalassemia , hemoglobin e , allele , genetics , beta thalassemia , biology , hemoglobin f , medicine , genotype , fetus , gene , pregnancy
Thalassemia is a monogenic hematologic disease that has the highest prevalence globally. In addition, there is complexity of the genetic background associated with a variety of phenotypes presented among patients. Genetic heterogeneity related to fetal hemoglobin (HbF) production has been reported as an influencing phenotypic factor of β-thalassemia (β-thal). Therefore, this study aimed to find the effect of these genetic modifiers, especially in the XmnI locus, rs11886868, rs766432 (BCL11A), and rs9399137 (HBS1L-MYB), among β-thal and HbE/β-thal patients in Indonesia, according to laboratory and clinical outcomes, including HbF levels and clinical scores. This study was also designed to compare these modifying effects among β-thal and HbE/β-thal patients in Indonesia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom